IC
FDMT icon

Ikarian Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Ikarian Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40
Closed -$223 – 187
2024
Q4 		$223 Buy
40
+1
+3% +$8 ﹤0.01% 170
2024
Q3 		$421 Buy
+39
New +$647 ﹤0.01% 145

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital's FDMT Position: Q1 2025 in Review

Ikarian Capital sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 40 shares — an estimated $223 sold.

Ikarian Capital first reported a position in FDMT in Q3 2024 and held it in 2 quarters. The position peaked at $421 in Q3 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Ikarian Capital reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 40 4D Molecular Therapeutics shares in Q1 2025, an estimated $223.
  • Ikarian Capital first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 2 quarters.
  • Ikarian Capital's 4D Molecular Therapeutics position peaked at $421 in Q3 2024.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.